Our shared vision is to build a strong portfolio of innovative products in support of existing customer requirements as we invest tirelessly in the development or acquisition of novel technologies to advance patient outcomes and increase our value proposition.
HUNTSVILLE, Ala. (PRWEB) November 10, 2020
Huntsville, AL, based spinal implant manufacturer Curiteva, Inc announced record revenue for Q3 2020 with the successful launch of their Prodigy Open and MIS posterior fixation systems. The company recorded 6 consecutive quarters of revenue growth since the launch of their first product in January of 2019 and currently has over 200 surgical kits in circulation around the United States.
Curiteva is a privately held technology and manufacturing company founded by Chad Falciani and Eric Linder in 2017. Mr. Falciani is the founder of multiple precision manufacturing, medical device, and biologic companies he led to successful exits over the last 20 years and serves as Chairman of the Board. “I saw a need for a platform company in the spinal implant space that combined world-class manufacturing with accelerated R&D, experienced leadership, and strong business principles,” said Falciani. Mr. Linder serves as Chief Technology Officer and has developed more than 25 FDA cleared systems in spine and orthopedics during his career.
The commitment to a diversified platform business supporting contract customers and introduction of Curiteva branded implant systems enabled the company to expand operations and infrastructure through the COVID-19 shut-down of elective procedures. “Our experience and expertise in designing and building precision implants and instruments allowed us to dedicate resources and equipment to support our contract customers and ensure we remained fully operational through this challenging time,” stated Bill Voss, Chief Operating Officer and 20+ year industry leader in medical device manufacturing.
The release of the Prodigy posterior fixation systems complements a portfolio that includes PLIF, TLIF, ALIF, and ACDF interbody and fixation systems developed in-house since 2017. “Our shared vision is to build a strong portfolio of innovative products in support of existing customer requirements as we invest tirelessly in the development or acquisition of novel technologies to advance patient outcomes and increase our value proposition,” commented CEO Mike English.
Mr. English added, “I am honored to work with these experienced leaders and the extraordinary team we support at Curiteva. We are grateful for the frontline healthcare workers, hospital administrators, and independent distributors who sacrificed daily to deliver our products and services to patients in need during this pandemic.”
Curiteva indicated additional announcements are coming prior to the end of 2020.
Curiteva is a privately held technology and manufacturing company dedicated to advancing spine surgery and improving clinical outcomes by partnering with providers and suppliers to deliver innovative and intuitive implant systems to the market. Our business is founded on a commitment to building world-class manufacturing, accelerating research and development, maintaining lean operational discipline, and delivering novel technology to meet the evolving needs of our customers and the patients they serve. For more information, please visit http://www.curiteva.com.